First Berlin: Valneva SE still has a buy rating and a price target of 8.6 euros

First Berlin: Valneva SE still has a buy rating and a price target of 8.6 euros

First Berlin Equity Research continues to rate Valneva SE as Buy and has a price target of EUR 8.6. Analysts at First Berlin Equity Research are optimistic, basing their assessment on the positive results for 2023, which showed an improvement in medium-term visibility in several key areas as well as upward revisions to the guidance. Additionally, Valneva has announced an 18-month extension of the interest-free period on USD100 million of debt. This measure means that the company will not have to repay debt in 2024 or 2025. Valneva is expected to generate consistently positive free cash flow following the planned launch of its Lyme disease vaccine in 2027, without further diluting shareholders.